Michael S. Spector

Tiger Management LLC is an independent hedge fund manager founded by Julian Robertson in 1980. Headquartered in New York City, the firm manages Mr. Robertson's personal assets.

Paramount BioCapital, Inc. is an alternative investment manager. The private company is based in New York, NY and has subsidiaries in the United States.

Morgan Stanley & Co. LLC is a registered broker-dealer subsidiary of Morgan Stanley Domestic Holdings, Inc., ultimately owned by Morgan Stanley (NYSE: MS) in the US. Headquartered in New York City, the firm was founded in 1987 and provides debt and equity services including underwriting, M&A advice, securities dealing and brokerage and trade execution. Their client base ranges from large global institutional investors to hedge funds at the cutting edge of innovation in the industry.

Part of Morgan Stanley, Morgan Stanley Japan Ltd. is a Japanese company that provides investment banking and institutional securities services. The company is based in Tokyo, Japan.

TransForm Pharmaceuticals, Inc. develops and manufactures drugs. It integrates pharmaceutical sciences, materials science and high throughput experimentation by enabling novel technology. The company was founded by Nicholas Galakatos in 1999 and is headquartered in Lexington, MA.

Ladenburg Thalmann & Co., Inc. provides investment baking and brokerage services. The firm also provides asset and wealth management, underwriting, alternative investments and advisory services. It serves emerging growth companies and high net worth individuals. The company was founded in 1876 and is headquartered in New York, NY.

PMSV Holdings LLC functions as an investment holding private company. The company is based in New York, NY.

Paramount BioSciences LLC (Paramount) is a venture capital firm founded in 1991. The firm is headquartered in New york.

Opus Point Partners Management LLC (OPPM) is a hedge fund manager headquartered in New York City. The firm was founded by Lindsay Rosenwald and Michael Weiss in 2009. They are owned by Opus Point Partners LLC, which is a subsidiary of Weiss & Co. LLC. OPPM manages investments that are dedicated to healthcare and life science.

venBio Partners LLC (venBio) is a venture capital subsidiary of Venbio Partners LP founded in 2009 by Adelman robert and Goodman corey. The firm is headquartered in San Francisco, California.

ALUS Liquidation Corp. develops, manufactures, and sells medical products. The company is based in Irvine, CA.

Avoro Capital Advisor LLC (AVCAP) is a SEC-registered investment advisor and hedge fund management subsidiary of Avoro Capital LP. The firm was founded by Corey Goodman in 2009 as venBio Select Advisor LLC. In 2019, a strategic transaction was closed whereby venBio Select Advisor LP entered into an agreement to sell their wholly-owned subsidiary, venBio Select Advisor LLC, the investment manager of the venBio Select Funds, to a newly formed holding company, Avoro Capital LP. Headquartered in New York, AVCAP provides investment advice and management to privately placed investment funds and separately managed accounts for high net-worth individuals.

Helocyte, Inc. engages in the development and commercialization of immunotherapies for the prevention and treatment of cytomegalovirus or CMV (cancer and infectious disease). It focuses on developing PepVax, a HLA-restricted single antigen peptide vaccine for controlling CMV in allogeneic hematopoietic stem cell transplant recipients and Triplex. The company was founded by Donald J. Diamond in 2015 and is headquartered in New York, NY.

Cellenkos, Inc. is a clinical biotechnology company. It focuses on umbilical cord blood derived T-regulatory cellular therapies for treating autoimmune diseases and inflammatory disorders. The company was founded by Simrit Parmar in September 2016 and is headquartered in Houston, TX.

Part of Fortress Biotech, Inc., Cyprium Therapeutics, Inc. is an American New York-based company focused on developing novel therapies for the treatment of Menkes disease and related copper metabolism disorders. The company was granted FDA breakthrough therapy, fast track, and rare pediatric disease designations, as well as FDA orphan drug designation for both Cutx-101 and AAV-ATP7A. The European Medicines Agency also granted orphan drug designation to Cyprium. In March 2017, Cyprium entered into a cooperative research and development agreement with the Eunice Kennedy Shriver National Institute of Child Health and Human Development to advance the clinical development of Cutx-101 for the treatment of Menkes disease. In 2023, Cyprium completed the transfer of its proprietary rights and assigned its FDA documents pertaining to Cutx-101 to Sentynl Therapeutics, Inc. Cyprium and NICHD also previously entered into a worldwide, exclusive license agreement to develop and commercialize AAV-ATP7A gene therapy, which is currently in pre-clinical development. The company was founded in 2017 by Michael Sean Weiss, Lindsay Allan Rosenwald, and Lung S. Yam, who has been the CEO since then.

Baergic Bio, Inc. develops therapeutic drugs for the treatment of central nervous system disorders. It offers oncology, rare diseases, and gene therapy. The company is headquartered in New York, NY.